Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period) and full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The domestic medical equipment market, the US water treatment market, and the semiconductor and LCD markets in China, Taiwan and South Korea, among others, performed strongly, and net sales are expected to exceed the previous forecast, partly due to the impact of foreign currency translation from the weaker yen. In addition, sales growth is expected to advance inventory optimisation and improve the cost-of-sales ratio, resulting in higher profit at each stage.
| Item | Details |
|---|---|
| Net Sales | Interim period 25,189; full year 50,959 → Interim period 26,893; full year 54,175（Interim period 6.8; full year 6.3） |
| Operating profit | Interim period 3,067; full year 6,428 → Interim period 3,990; full year 7,537（Interim period 30.1; full year 17.3） |
| Ordinary income | Interim period 3,346; full year 6,986 → Interim period 4,577; full year 8,655（Interim period 36.8; full year 23.9） |
| Profit attributable to owners of the parent | Interim net income 2,307; full-year net income 5,149 → Interim net income 3,392; full-year net income 6,437（Interim period 47.0; full year 25.0） |
| Net income per share | Interim period 103.95; full year 231.94 → Interim period 152.85; full year 289.57（Interim period 47.0; full year 24.8） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Interim period of the fiscal year ended March 2026: net sales ¥22,693 million, operating profit ¥2,726 million, ordinary profit ¥3,231 million, interim net income ¥2,299 million, interim net income per share ¥103.82. Full year of the fiscal year ended March 2026: net sales ¥47,692 million, operating profit ¥5,924 million, ordinary profit ¥6,724 million, net income ¥4,835 million, net income per share ¥218.14. |
| Reason for the revision | The domestic medical equipment market, the US water treatment market, and the semiconductor and LCD markets in China, Taiwan and South Korea, among others, performed strongly, and net sales are expected to exceed the previous forecast, partly due to the impact of foreign currency translation from the weaker yen. In addition, sales growth is expected to advance inventory optimisation and improve the cost-of-sales ratio, resulting in higher profit at each stage. |
| Dividend forecast revision | The second-quarter dividend forecast remains unchanged at ¥45.00. The year-end dividend forecast was increased from ¥47.00 to ¥67.00, and the annual dividend forecast was increased from ¥92.00 to ¥112.00. The second-quarter dividend includes a commemorative dividend of ¥10. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The domestic medical equipment market, the US water treatment market, and the semiconductor and LCD markets in China, Taiwan and South Korea performed strongly, while the impact of foreign currency translation due to the weaker yen also boosted net sales. In addition, inventory optimisation improved the cost-of-sales ratio, resulting in upward revisions to profit at each stage.